• GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics

    InvestorPlace - Stock Market News, Stock Advice & Trading Tips GBT stock is already rallying on takeover talk. Now that Pfizer has confirmed the buyout, Global Blood Therapeutics is red hot. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now. ...

  • Pfizer To Acquire Blood Disorder Drugmaker Global Blood Therapeutics For $5.4B

    Pfizer Inc. (NYSE:PFE) has reached an agreement to acquire Global Blood Therapeutics Inc (NASDAQ:GBT) in a deal with $5.4 billion. The addition of the blood disorder drugmaker will boost Pfizer’s drug pipeline. It’s the latest in a series of acquisitions aimed at supporting Pfizer as it approaches a potential slowdown in COVD-19 products as cases […]

    • Invezz

    Pfizer is acquiring Global Blood Therapeutics

    Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share. The agreement further improves and complements Pfizer Inc’s over three-decade-long heritage in […]

  • Pfizer to acquire Global Blood Therapeutics for $5.4B

    Pfizer nabbed a $5.4 billion deal to acquire sickle cell drugmaker Global Blood Therapeutics, according to an Aug. 8 press release. 

  • Pfizer agrees to $5.4B deal for Global Blood Therapeutics

    Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease.

  • Pfizer Buying Global Blood Therapeutics In $5.4B Deal

    NEW YORK (AP) – Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 […]

    • WTMJ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic

  • Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic

    • KESQ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 million last year. Pfizer

    • KESQ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 million last year. Pfizer

  • Pfizer Buys Global Blood Therapeutics In $5.4 Billion Deal

    Pfizer Inc. agreed on Monday to pay $5.4 billion in cash for Global Blood Therapeutics, a maker of sickle cell drugs, as it seeks to cash in on increased revenue from its COVID-19 vaccine and treatment. Pfizer will pay $68.50 per GBT share, representing a 7.3% premium to Friday’s closing price. The deal carries a […]

  • Pfizer to Acquire Global Blood Therapeutics, Achieves Long-Time Goal

    Pfizer is acquiring Global Blood Therapeutics in a deal valued at $5.4 billion, which helps Pfizer realize its long-time goal of having a sickle-cell disease portfolio.